Carbohydrate Active Ingredients TRIZ Cases
- Dapagliflozin Therapy for HFpEF With Preserved Ejection Fraction
Dapagliflozin targets SGLT2 to improve diastolic function, reduce fibrosis, and lower HFpEF hospitalization and cardiovascular risk.
- RXFP1 Modulator Combinations with SGLT2 Inhibitors for Longer Action
Combining RXFP1 modulators with SGLT2 inhibitors extends therapeutic action and supports treatment of hypertension, heart failure, and CKD.
- BET Bromodomain and SGLT2 Combination Therapy for MACE Reduction
Combining a BET bromodomain inhibitor with an SGLT2 inhibitor addresses recurrent MACE risk after ACS, especially in type 2 diabetes.
- Zibotentan-Dapagliflozin Combination for CKD Fluid Balance
Pairing zibotentan with dapagliflozin offsets fluid retention and hemoconcentration while improving CKD renal protection.